How will the tie-up with Dr. Reddy’s Laboratories help India?
The story so far: On September 16, Hyderabad-based Dr. Reddy’s Laboratories announced that it had signed an agreement with the Russian Direct Investment Fund (RDIF) to conduct large human trials (Phase-3) of Sputnik V. A candidate vaccine for COVID-19, it has been developed by Russia’s Gamaleya Research Institute and piloted by the RDIF, the country’s sovereign wealth fund. If these trials are successful and the vaccine is proved to be safe, Russia has committed itself to supplying 100 million doses to India through Dr. Reddy’s.
What do we know about Sputnik V?
Much like the launch of the Sputnik-1 satellite in 1957 heralded the Space Age, Russia claims the vaccine candidate will “reinvigorate” vaccine development and a potential solution to the coronavirus pandemic. Sputnik V is being developed as a…